Notably, mutations in the genes encoding isocitrate dehydrogenase (IDH)-1 and IDH-2 have been described in 5% of de novo GBM and more than 90% of secondary GBM [review in (81)]. This evidence concerns the gene IDH1 and glioblastoma.